Cash Runway Analysis for Hong Kong IPOs: Enough Cash Until Next Funding Round

The Hong Kong Stock Exchange’s (HKEX) Listing Committee issued guidance in December 2024 (GL126-24) tightening the disclosure requirements for pre-IPO cash flow projections, directly impacting how sponsors and listing applicants calculate and present their cash runway. This shift comes as 42% of new listings on the Main Board in the first half of 2025 disclosed a cash runway of less than 12 months from the listing date, a figure up from 28% in the same period of 2023, according to HKEX’s IPO Review 2025 (H1). For analysts and investors, the stated “sufficient cash for 12 months” language in a prospectus no longer provides adequate cover; the market now demands a granular, scenario-based analysis of burn rate, revenue conversion cycles, and the precise trigger points for the next funding round. This article dissects the mechanics of cash runway analysis for Hong Kong IPOs, using the HKEX Listing Rules and SFC’s Code of Conduct as the analytical framework, to equip readers with the tools to assess whether a listed entity’s cash position is a buffer or a countdown.

The Regulatory Framework: From “Going Concern” to “Runway Precision”

HKEX Listing Rules and the 12-Month Benchmark

The foundational requirement for any Hong Kong IPO applicant is set out in HKEX Listing Rule 9.04(2), which mandates that the listing document must contain a statement by the directors that, in their opinion, the group has sufficient working capital for its present requirements for at least the next 12 months from the date of the prospectus. This is not a discretionary forecast; it is a hard requirement for listing approval. The sponsor (保薦人) must independently verify this statement, typically through a working capital report (WCR) that models the company’s cash flows under base case and downside scenarios.

The December 2024 guidance (GL126-24) explicitly requires the WCR to include a sensitivity analysis showing the impact of a 10% revenue decline, a 15-day extension in debtor days, and a 20% increase in operating expenses. For a biotech company listing under Chapter 18C, for example, which has no revenue to model, the HKEX expects the WCR to focus on the cash burn rate against the remaining R&D milestones. In practice, this means a company with HKD 200 million in cash on the balance sheet and a monthly burn rate of HKD 20 million has exactly 10 months of runway. If the downside scenario pushes the burn rate to HKD 25 million, the runway drops to 8 months, triggering a mandatory disclosure in the risk factors section.

SFC’s Code of Conduct and Sponsor Due Diligence

The Securities and Futures Commission (SFC) reinforces this through paragraph 17.6 of its Code of Conduct for Persons Licensed by or Registered with the SFC, which requires sponsors to conduct “reasonable due diligence” on the working capital projections. The SFC’s enforcement track record is clear: in 2023, the SFC reprimanded and fined two sponsors (HKD 15 million combined) for failing to adequately verify a listing applicant’s cash flow projections, specifically for not challenging management’s assumption that debtor days would improve from 90 to 60 days post-listing—an assumption that proved materially incorrect within six months of listing.

For the analyst or family office principal, this means the sponsor’s WCR is a critical document. The key data points to extract are: (i) the base case monthly burn rate, (ii) the downside case burn rate, (iii) the assumed revenue conversion cycle (cash conversion cycle), and (iv) the specific trigger points for the next equity or debt financing. If the prospectus states “we believe we have sufficient cash for the next 12 months” without disclosing these underlying assumptions, the risk of a near-term dilutive fundraising rises significantly.

Deconstructing the Cash Runway: Beyond the Balance Sheet

The Cash Conversion Cycle (CCC) as the Primary Driver

Cash runway is not simply cash on hand divided by monthly operating expenses. The cash conversion cycle (CCC)—the number of days between paying for raw materials or inventory and receiving cash from customers—is the real determinant of liquidity. For a Main Board IPO applicant in the manufacturing sector, a CCC of 120 days means that every HKD 1 million in revenue requires HKD 1 million in working capital for four months before cash is collected. If the company is growing revenue at 30% year-on-year, the working capital requirement grows faster than the revenue, potentially compressing the cash runway.

Take the example of a consumer goods company listing on the Main Board in 2025 with HKD 500 million in cash and HKD 1.2 billion in annual revenue. The prospectus states a 12-month runway. However, the CCC is 150 days (inventory: 60 days, receivables: 90 days, payables: 30 days). A revenue growth assumption of 25% in the first year post-listing requires an additional HKD 125 million in working capital (25% of HKD 500 million in working capital tied up in the CCC). This effectively reduces the cash available for operations by HKD 125 million, shortening the real runway from 12 months to approximately 9 months. The HKEX’s GL126-24 now requires this working capital growth to be explicitly modeled in the WCR.

The “Next Funding Round” Trigger

The article’s title poses a critical question: “enough cash until next funding round.” For a pre-revenue biotech (Chapter 18C) or a pre-profit tech company (Chapter 18A), the next funding round is not a hypothetical; it is a planned event. The prospectus must disclose the expected timeline for the next financing. The key metric is the “cash runway to key milestone” ratio. If a biotech company has HKD 300 million in cash and a monthly burn of HKD 15 million, the runway is 20 months. If the next key milestone (e.g., Phase 2 trial data) is 18 months away, the company has a 2-month buffer. If the milestone is 24 months away, the company will need a bridge financing at month 20, likely at a discounted valuation.

The SFC’s Code of Conduct (paragraph 17.6) requires the sponsor to assess the reasonableness of the company’s ability to raise that next round. This includes evaluating the company’s pipeline, comparable company valuations, and the availability of capital in the market. For the investor, the prospectus should disclose the assumed valuation for the next round. If the company assumes a 20% premium to its IPO price for a round 12 months post-listing, but the market for its sector has contracted by 15%, the gap between expectation and reality will force a down-round, diluting existing shareholders.

Sector-Specific Runway Dynamics: Biotech, Tech, and Traditional Enterprises

Biotech (Chapter 18C): The Burn Rate and Milestone Dependency

Biotech companies listing under HKEX Chapter 18C (for specialist technology companies) or Chapter 18A (for biotech) are the most cash-runway-sensitive. These entities have no revenue, so the cash runway is purely a function of the burn rate and the timing of the next funding round. The prospectus must disclose the “expected cash runway to the next key milestone” and the “expected date of the next financing.” The HKEX’s guidance (GL126-24) requires the WCR to include a scenario where the next financing is delayed by 6 months.

For a biotech with a monthly burn of HKD 10 million and HKD 180 million in cash, the base case runway is 18 months. If the next key milestone (e.g., FDA IND approval) is expected at month 12, the company has a 6-month buffer. However, if the FDA approval is delayed by 3 months (a common occurrence), the runway post-milestone drops to 3 months, forcing the company to seek a bridge loan or an equity line at unfavorable terms. The investor should calculate the “runway to zero” under a 6-month delay scenario. If that figure is less than 3 months, the company is effectively insolvent without a new financing, a fact that must be disclosed in the risk factors.

Tech (Chapter 18A): The Gross Margin and Revenue Growth Trade-off

For pre-profit tech companies listing under Chapter 18A (or Chapter 18C for specialist tech), the cash runway is a function of gross margin and revenue growth. A company with 40% gross margins and 50% year-on-year revenue growth will have a negative operating cash flow until the gross profit covers the fixed costs (R&D, sales, G&A). The cash runway is the time until the company reaches that “cash flow break-even” point.

If the prospectus states a cash runway of 18 months, but the company’s revenue growth rate is decelerating (from 50% to 30%), the time to break-even extends. The WCR should model this deceleration. For example, a company with HKD 400 million in cash, a monthly operating cash burn of HKD 15 million, and a projected break-even at month 15 has a 3-month buffer. If revenue growth slows to 20%, the break-even shifts to month 20, and the company runs out of cash at month 18. The investor must verify that the WCR includes a “growth deceleration” scenario.

Traditional Enterprises: The Dividend and Capex Trap

For traditional Main Board listings (retail, manufacturing, property), the cash runway is often overshadowed by dividend commitments and capital expenditure (capex) plans. A company may have HKD 1 billion in cash, but if it has committed to a HKD 500 million dividend payout in the first year and HKD 400 million in capex, the available cash for operations is only HKD 100 million. The cash runway is then measured against the operating cash flow deficit.

The HKEX Listing Rules (Rule 9.04(2)) do not explicitly require the WCR to subtract committed dividends and capex from the cash balance, but the sponsor’s due diligence should. The investor should calculate “adjusted cash runway” = (Cash + Marketable Securities – Committed Dividends – Committed Capex) / Monthly Operating Cash Burn. If this figure is less than 12 months, the company is effectively relying on future operating cash flow to fund these commitments, a risk that should be flagged.

Actionable Takeaways for Investors and Analysts

1. Always request the sponsor’s working capital report (WCR) summary. The prospectus’s “12-month runway” statement is a floor, not a ceiling; the WCR’s downside scenario reveals the true risk of a near-term dilutive fundraising.
2. Calculate the “adjusted cash runway” by subtracting committed dividends, capex, and working capital growth from the cash balance. The raw cash-on-hand figure is misleading for companies with high growth or large capital commitments.
3. For biotech and pre-revenue tech, compute the “runway to zero under a 6-month delay scenario.” If this figure is less than 3 months, the company is at high risk of a forced down-round or bridge financing.
4. Verify the cash conversion cycle (CCC) and its trend. A deteriorating CCC (e.g., debtor days increasing from 60 to 90) is a leading indicator of a cash crunch, regardless of the stated runway.
5. Cross-reference the expected next funding round valuation with comparable company multiples. If the assumed valuation is more than 20% above the current sector average, the risk of a dilutive down-round is material.